Valerie B. Palmieri

Executive Chairwoman of the Board

Valerie Palmieri was appointed Executive Chairwoman of the Board on March 1, 2022. Prior to this Valerie served as President and CEO of Aspira Women's Health from January 2015, initially joining Aspira Women's Health as Chief Operating Officer in October 2014.

During her tenure at Aspira Women’s Health, Valerie was the architect of the company’s mission, vision and strategy which has led to the company becoming a premier women’s health enterprise. This began with the endorsement of OVA1 by medical society guidelines, payer coverage for the majority of the lives the US,  the creation of a second generation technology, developing an expanded high growth product pipeline known as the “Patient Lifecycle”, and ultimately creating a new corporate brand to serve the company for years to come. OVA1 has touched over 155,837 patient lives to date.

Valerie brings to Aspira Women's Health close to 40 years of experience in the diagnostic laboratory industry, serving in numerous sales, operations, and executive leadership positions for both laboratory service and consulting organizations. Before joining Aspira Women's Health, Palmieri was CEO/President of MOMENTUM Consulting, a national strategic life science consulting practice. She also served as CEO/President of two healthcare start-ups that resulted in a successful exit for one and won her recognition as one of the “Top 10 US Entrepreneurs of Springboard Enterprises” for the other. She spent six years as National Vice President of Anatomic Pathology Operations with LabCorp, the successor company to DIANON Systems where she served as Senior Vice President of Operations and was a key leader in the sale of DIANON to LabCorp in 2003.

She currently serves on the Life Science Council and the Women’s Health Innovation Council at Springboard Enterprises, a non-profit focused on accelerating the growth of female led entrepreneurial companies.  Ms. Palmieri holds a Bachelor of Science degree in Medical Technology from Western Connecticut State University.

James T. LaFrance

 Lead Independent Director and Audit Committee Chair

James T. LaFrance became a director of Aspira Women's Health and was elected Chairman of the Board in December 2013. He served as President and Chief Executive Officer from April to December 2014. He has over thirty years of diagnostic industry experience. Most recently, LaFrance was head of digital pathology and CEO of Omnyx, LLC for GE Healthcare. Prior to that, he held a series of commercial, strategic marketing and business development leadership roles at Ventana Medical Systems (now Roche Tissue Diagnostics), including general manager of their North American and International commercial organizations. Prior to Ventana, LaFrance served in leadership roles in global marketing and business development at Bayer Diagnostics. Jim currently serves on the board of HTG Molecular in Tucson and Personal Genome Diagnostics in Baltimore. Jim is also on the Advisory Board of PathAi in Boston. He earned a Bachelor of Arts degree in economics from the University of Connecticut and an MBA from the University of Notre Dame.

Celeste Fralick

Director

Dr. Celeste Fralick joined the board of Aspira Women's Health in March 2022. She is a senior technical leader with over four decades of industry experience (McAfee, Intel, Medtronic, Fairchild, and Texas Instruments). Her process, product, and system expertise spans statistics, ML, DL, and AI in innovation, development, and implementation in 10 different markets. She was named to Forbes “Top 50 Women in Technology” (2018) and CDO’s “Global Data Power Women” (2020, 2021), and has numerous patents, scholarly and media articles. She represents shareholders and industry on four different Boards and is Managing Partner, Purkinje Science and Technology, LLC. Dr. Fralick has a Ph.D. in Biomedical Engineering from Arizona State University, concentrating in neural networks, bioelectricity, and neuroscience.

Dr. Robert Auerbach

Director

Dr. Robert Auerbach joined the board of Aspira Women's Heath in June 2022. He retired in 2020 as President of CooperSurgical Inc., a wholly-owned subsidiary of CooperCompanies. Having joined CooperSurgical in 2005, Dr. Auerbach previously held Executive Vice President positions, including Chief Medical Officer and Chief Strategy Officer. Dr. Auerbach continues to serve as an adjunct faculty member and as an Executive Board Member of the Center for Biomedical Innovation and Technology (CBIT) at Yale University and has also been a member of the Yale School of Medicine clinical faculty.  He currently serves on the Board of Directors of OCON Healthcare, Escala Medical, Empress Medical, AblaCare, as well as an advisor to CooperSurgical and GestVision. He is a graduate of the Lehigh-Hahnemann 6-year BA-MD program and completed his OB/GYN residency at Yale.

Ms. Ruby Sharma

Director

Ms. Ruby Sharma joined the Aspira Women's Health board in June 2022. She is a seasoned professional and qualified audit committee financial expert, is a Managing Partner at RNB Strategic Advisors. Ruby serves as a member of the board of directors of Nautilus, Inc. (NYSE: NLS) and ShotSpotter, Inc. (NASDAQ: SSTI) and previously served as a Trustee and chair of the audit committee at Penn Medicine Princeton Health. Ruby retired in 2017 as Senior Partner from Ernst & Young LLP and has also held senior management positions with Arthur Andersen, LLP and Grant Thornton GmbH. Ms. Sharma is a Fellow Chartered Accountant and holds a B. A. in Economics from Delhi University, India. Ms. Sharma has also attended Executive Education program for EY Partners at Northwestern University, Kellogg School of Management.